Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration builds on research from the team of Dr. Daniel Levesque at UdeM, and focuses on the design of highly selective modulators of the Nur77/RXR nuclear receptor complex, a promising new pharmacological target for movement disorders.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Université de Montréal
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 10, 2021